[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340323-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-340323-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-clinically-effective-model-based-on-cell-free-dna-methylation-and-low-dose-ct-for-risk-stratification-of-pulmonary-nodules","A Clinically Effective Model Based on Cell-Free DNA Methylation and Low-Dose CT for Risk Stratification of Pulmonary Nodules","","Accurate, non-invasive, and cost-effective tools are needed for pulmonary nodule diagnosis and management as low-dose computed tomography (LDCT) detects increasing numbers of nodules. Genome-wide methylation sequencing identified 263 differential DNA methylation regions from malignant and non-malignant lung tissues, enabling a targeted panel tested on blood cell-free DNA (cfDNA) in two multicenter cohorts. An integrative machine-learning model using 40 cfDNA methylation biomarkers, age, and five CT features achieved strong risk stratification, and a two-threshold strategy reduced unnecessary invasive surgery and overtreatment while guiding timely management for lung cancer.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-clinically-effective-model-based-on-cell-free-dna-methylation-and-low-dose-ct-for-risk-stratification-of-pulmonary-nodules/340323/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-clinically-effective-model-based-on-cell-free-dna-methylation-and-low-dose-ct-for-risk-stratification-of-pulmonary-nodules/340323.png","ImageObject",300,407,{"name":42,"@type":43},"Skyler","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What data sources are used to build the risk stratification model?","Question",{"text":63,"@type":64},"The model integrates blood cell-free DNA (cfDNA) methylation biomarkers, patient age, and five simple computed tomography (CT) imaging features.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the methylation biomarker panel developed?",{"text":68,"@type":64},"Genome-wide methylation sequencing on malignant and non-malignant lung tissues identified 263 differential methylation regions, which were distilled into a targeted panel and applied to cfDNA using prospective/retrospective multicenter cohorts.",{"name":70,"@type":61,"acceptedAnswer":71},"What does the two-threshold strategy achieve clinically?",{"text":72,"@type":64},"It aims to reduce unnecessary invasive surgeries, overtreatment costs, and injury for patients with benign nodules, while advising immediate treatment for patients with lung cancer.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340323,1790321346,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336464648746,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Article  \nA clinically effective model based on cell-free DNA methylation and low-dose CT for risk stratiﬁcation of pulmonary nodules  \nAuthors  \nWenhua Liang, Jinsheng Tao, Chao Cheng, ..., Nanshan Zhong, Jian-Bing Fan, Jianxing He  \nCorrespondence  \n[jianbingfan1115@smu.edu.cn](jianbingfan1115@smu.edu.cn) (J.-B.F.),  \n[drjianxing.he@gmail.com](drjianxing.he@gmail.com) (J.H.),  \n[liangwh1987@163.com](liangwh1987@163.com) (W.L.)  \nIn brief  \nLiang et al. present an integrated model consisting of 40 lung-cancer-speciﬁccfDNA methylation markers, one clinical feature, and ﬁve CT imaging features for non-invasively accurate diagnosis and management of pulmonary nodules. The two-threshold strategy of the model can reduce unnecessary invasive surgeries and improve the overall diagnosis of lung cancer.  \nd A concise methylation biomarker panel can non-invasively classify pulmonary nodules  \nd The methylation model outperforms clinical tools in classifying pulmonary nodules  \nd Five simple CT features and age signiﬁcantly improve the diagnostic performance  \nd Two-threshold strategy enables accurate risk stratiﬁcation of pulmonary nodules  \nLiang et al., 2024, Cell Reports Medicine 5, 101750  \nOctober 15, 2024 ª 2024 The Author(s) . Published by Elsevier Inc.  \n[https://doi.org/10.1016/j.xcrm.2024.101750](https://doi.org/10.1016/j.xcrm.2024.101750)  \nll  \nll  \nOPEN ACCESS  \nArticle  \nA clinically effective model based on cell-free DNA methylation and low-dose CT for risk stratiﬁcation of pulmonary nodules  \nWenhua Liang,1,12,* Jinsheng Tao,2,12 Chao Cheng,3,12 Haitao Sun,4,12 Zhujia Ye,2,12 Shuangxiu Wu,2 Yubiao Guo,5 Jiaqing Zhang,6 Qunqing Chen,6 Dan Liu,7 Lunxu Liu,8 Hui Tian,9 Lin Teng,2 Nanshan Zhong,10 Jian-Bing Fan,2,11,* and Jianxing He1,13,*  \n1Department of Thoracic Surgery and Oncology, The First Afﬁliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Disease & Health, China State Key Laboratory and National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China  \n2AnchorDx Medical Co. , Ltd. , Guangzhou 510320, China  \n3Department of Thoracic Surgery, The First Afﬁliated Hospital of Sun Yat-sen University, Guangzhou 510080, China  \n4Clinical Biobank Center, Guangdong Provincial Clinical Research Center for Laboratory Medicine, Department of Laboratory Medicine, Microbiome Medicine Center, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China  \n5Department of Pulmonary Medicine, The First Afﬁliated Hospital of Sun Yat Sen University, Guangzhou 510080, China  \n6Department of Thoracic Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510280 China  \n7Department of Respiratory Medicine, West China Hospital of Sichuan University, Chengdu 610041, China  \n8Department of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu 610041, China  \n9Department of Thoracic Surgery, QILU Hospital, Shandong University, Jinan 250012 China  \n10Department of Respiratory Medicine, The First Afﬁliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Disease & Health, China State Key Laboratory and National Clinical Research Center for Respiratory Disease, Guangzhou, 510120, China  \n11Department of Pathology, School of Basic Medical Science, Southern Medical University, Guangzhou 518055, China  \n12These authors contributed equally  \n13Lead contact  \n*Correspondence: jianbingfan1[115@smu.edu.cn](115@smu.edu.cn) (J.-B.F.), [drjianxing.he@gmail.com](drjianxing.he@gmail.com) (J.H.), [liangwh1987@163.com](liangwh1987@163.com) (W.L.) [https://doi.org/10.1016/j.xcrm.2024.101750](https://doi.org/10.1016/j.xcrm.2024.101750)  \nSUMMARY  \nAccurate, non-invasive, and cost-effective tools are needed to assist pulmonary nodule diagnosis and management due to increasing detection by low-dose computed tomography (LDCT) . We perform genome-wide methylation sequencing on malignant and non-malignant lung tissues and designed a panel of 263 dif","cbCaigX3eK3DrAsD","https://ap.wps.com/l/cbCaigX3eK3DrAsD","pdf",4765875,18,"English","# Summary\n# Introduction\n# Methods and Model Development\n# Model Validation\n# Two-Threshold Strategy and Clinical Implications","[{\"question\":\"What data sources are used to build the risk stratification model?\",\"answer\":\"The model integrates blood cell-free DNA (cfDNA) methylation biomarkers, patient age, and five simple computed tomography (CT) imaging features.\"},{\"question\":\"How was the methylation biomarker panel developed?\",\"answer\":\"Genome-wide methylation sequencing on malignant and non-malignant lung tissues identified 263 differential methylation regions, which were distilled into a targeted panel and applied to cfDNA using prospective/retrospective multicenter cohorts.\"},{\"question\":\"What does the two-threshold strategy achieve clinically?\",\"answer\":\"It aims to reduce unnecessary invasive surgeries, overtreatment costs, and injury for patients with benign nodules, while advising immediate treatment for patients with lung cancer.\"}]","A Clinically Effective Model Based on Cell-Free DNA Methylation and Low-Dose CT for Risk Stratification of Pulmonary Nodules | PDF",1790035821,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c44d1f35d0c669c6996d10028d21a2c4.webp",983,1276,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cf964f0b6d54a19c357197119f8c3aed.webp",982,1275,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6d05200f84978e18f330475e2462fa34.webp",981,1273,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b5e59945bd86c69d270133b264dafc20.webp",980,1272]